ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Description

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

Conditions

Cardiovascular Risk, Acute Myocardial Infarction (AMI)

Study Overview

Study Details

Study overview

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Condition
Cardiovascular Risk
Intervention / Treatment

-

Contacts and Locations

Alexander City

Advanced Cardiovascular, LLC, Alexander City, Alabama, United States, 35010

Birmingham

Birmingham VA Medical Center, Birmingham, Alabama, United States, 35233

Birmingham

Grandview Medical Center, Birmingham, Alabama, United States, 35243

Fairhope

Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama, United States, 36532

Huntsville

Heart Center Rsrch_Hunstville, Huntsville, Alabama, United States, 35801

Mobile

Mobile Heart USA Health Cardiology Clinic, Mobile, Alabama, United States, 36606

Gilbert

Mercy Gilbert Medical Center, Gilbert, Arizona, United States, 85297

Phoenix

Mayo Clinic Arizona, Phoenix, Arizona, United States, 85054

Scottsdale

Honor Health, Scottsdale, Arizona, United States, 85258

Little Rock

Arkansas Cardiology Clinic, Little Rock, Arkansas, United States, 72205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Novo Nordisk A/S,

    Clinical Transparency dept. 2834, STUDY_DIRECTOR, Novo Nordisk A/S

    Study Record Dates

    2026-09-03